The scientific team
at Amira is responsible for an impressive portfolio of compounds,
including AM103/AM803, oral, next-generation inhibitors of 5-lipoxygenase-activating protein
(FLAP).
Since the company's founding in 2005,
Amira’s drug
hunters discovered five highly-targeted, novel compounds that progressed to GLP toxicity studies. Three of these compounds are currently being studied in humans.. |
